KEY WORDS: cancer patients, oral mucositis, prevention REVIEW QUESTION What are the effective interventions for preventing oral mucositis in patients with cancer receiving treatment?
SUMMARY OF KEY EVIDENCE
n Four trials compared allopurinol mouth rinse with placebo or no treatment, demonstrating a statistically significant difference in favor of allopurinol for preventing moderate plus severe mucositis, relative risk [RR] = 0.66 (95% confidence intervals [CI] 0.50Y0.86; P = .002), although substantial heterogeneity was noted. n Two trials compared aloe vera with placebo for oral mucositis in patients with head and neck cancer, showing that aloe vera was beneficial in the prevention of moderate to severe mucositis, RR = 0.74 (95% CI = 0.58Y0.96; P = .02). n Eleven trials compared amifostine with no treatment (8 trials were found to be at high risk of bias). These studies demonstrated a significant benefit for moderate plus severe mucositis, RR = 0.75 (95% CI = 0.58Y0.96; P = .02); a significant but small benefit for any mucositis, RR = 0.95 (95% CI = 0.91Y0.99; P = .007); and no statistically significant difference for severe mucositis. n Six trials evaluated the effectiveness of cryotherapy.
Statistically significant differences were found for each of the 3 outcome categories of mucositis: RR = 0.74 (95% CI = 0.57Y0.95) for any mucositis; RR = 0.53 (95% CI = 0.31Y0.91) for moderate plus severe mucositis; and RR = 0.36 (95% CI = 0.17Y0.77) for severe mucositis. n Three studies compared the use of intravenous glutamine supplementation with placebo using approximately 30 g/day or 20 g/day added to parenteral nutrition. They found a statistically significant decrease (75%) in severe mucositis associated with intravenous glutamine supplementation, RR = 0.25 (95% CI = 0.10Y0.62). All 3 trials were small (16Y48 participants) and were assessed as being at unclear risk of bias. n Weak evidence from 3 small studies showed that honey may be beneficial with regard to the prevention of each of 3 mucositis severities. However, considerable statistical heterogeneity and a high risk of bias should be emphasized when interpreting the results. n Seven trials compared keratinocyte growth factor (GF) with placebo, showing a statistically significant effect in favor of keratinocyte GF: RR = 0.82 (95% CI = 0.71Y0.94; P = .005) for any mucositis; RR = 0.74 (95% CI = 0.62Y0.89; P = .002) for moderate plus severe mucositis; RR = 0.72 (95% CI = 0.58Y0.90; P = .004) for severe mucositis. n Five studies compared laser with a sham laser placebo or no treatment control. There was a statistically significant reduction (80%) in the incidence of severe mucositis in the laser group compared with sham or no treatment control, RR = 0.20 (95% CI = 0.06Y0.62), but no statistically significant difference in the incidence of any mucositis or moderate plus severe mucositis. n Three trials compared polymixin, tobramycin, and amphotoricin (PTA) antibiotic pastille/paste with a placebo, demonstrating a statistically significant benefit favoring PTA for prevention of any mucositis, RR = 0.87 (95% CI = 0.78Y0.96; P = .008), in patients undergoing radiotherapy for head and neck cancers. n In addition, the Cochrane review presented data from single trials evaluating single comparisons. The statistically significant interventions were epidermal GF, intestinal trefoil factor, and Shenqi-fanghou; however, these results should be considered with caution. n Other interventions reported in the review reported no statistically significant effects.
BEST PRACTICE RECOMMENDATIONS
Nine interventions demonstrated some benefit with regard to preventing or reducing the severity of mucositis associated with cancer treatment. For patients with head and neck cancer undergoing radiotherapy, oral mucositis may be prevented by aloe vera, honey, or PTA pastilles/ paste. For patients with blood cancers undergoing chemotherapy or stem cell transplantation, cryotherapy may be effective. Other 5 interventions (allopurinol, amifostine, intravenous glutamine, keratinocyte GF, and laser treatment) were found to be effective in patients with different types of cancer, undergoing different treatments.
